• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雌激素受体-α36/表皮生长因子受体正反馈环路促进雌激素受体阴性乳腺癌细胞的恶性生长。

A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.

机构信息

Department of Medical Microbiology & Immunology, Creighton University Medical School, Omaha, NE, USA.

出版信息

Oncogene. 2011 Feb 17;30(7):770-80. doi: 10.1038/onc.2010.458. Epub 2010 Oct 11.

DOI:10.1038/onc.2010.458
PMID:20935677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3020987/
Abstract

It is prevailingly thought that estrogen signaling is not involved in development of estrogen receptor (ER)-negative breast cancer. However, there is evidence indicating that ovariectomy prevents the development of both ER-positive and -negative breast cancer, suggesting that estrogen signaling is involved in the development of ER-negative breast cancer. Previously, our laboratory cloned a variant of ER-α, ER-α36, and found that ER-α36 mediated nongenomic estrogen signaling and is highly expressed in ER-negative breast cancer cells. In this study, we found that ER-α36 was highly expressed in 10/12 cases of triple-negative breast cancer. We investigated the role of mitogenic estrogen signaling mediated by ER-α36 in malignant growth of triple-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of ER-α36 and found that these cells strongly responded to mitogenic estrogen signaling both in vitro and in vivo. Knockdown of ER-α36 expression in these cells using the small hairpin RNA method diminished their responsiveness to estrogen. ER-α36 physically interacted with the EGFR/Src/Shc complex and mediated estrogen-induced phosphorylation of epidermal growth factor receptor (EGFR) and Src. EGFR signaling activated ER-α36 transcription through an AP1 site in the ER-α36 promoter, and ER-α36 expression was able to stabilize EGFR protein. Our results, thus demonstrated that ER-α36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK signaling pathway in ER-negative breast cancer cells and suggested that a subset of ER-negative breast tumors that expresses ER-α36, retains responsiveness to mitogenic estrogen signaling.

摘要

普遍认为,雌激素信号不参与雌激素受体(ER)阴性乳腺癌的发生。然而,有证据表明,卵巢切除术可预防 ER 阳性和 ER 阴性乳腺癌的发生,这表明雌激素信号参与 ER 阴性乳腺癌的发生。以前,我们实验室克隆了 ER-α的一种变体 ER-α36,并发现 ER-α36 介导非基因组雌激素信号,并且在 ER 阴性乳腺癌细胞中高度表达。在这项研究中,我们发现 ER-α36 在 12 例三阴性乳腺癌中的 10 例中高度表达。我们研究了由 ER-α36 介导的促有丝分裂雌激素信号在表达高水平 ER-α36 的三阴性乳腺癌 MDA-MB-231 和 MDA-MB-436 细胞中的恶性生长中的作用,发现这些细胞对体外和体内的促有丝分裂雌激素信号强烈反应。使用短发夹 RNA 方法敲低这些细胞中的 ER-α36 表达,减弱了它们对雌激素的反应性。ER-α36 与 EGFR/Src/Shc 复合物相互作用,并介导雌激素诱导的表皮生长因子受体(EGFR)和 Src 的磷酸化。EGFR 信号通过 ER-α36 启动子中的 AP1 位点激活 ER-α36 转录,并且 ER-α36 表达能够稳定 EGFR 蛋白。我们的结果表明,ER-α36 通过 EGFR/Src/ERK 信号通路在 ER 阴性乳腺癌细胞中介导非基因组雌激素信号,并表明表达 ER-α36 的 ER 阴性乳腺癌肿瘤亚群保留对促有丝分裂雌激素信号的反应性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/fdabdb1e04f3/nihms233581f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/788dba5d1eb0/nihms233581f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/1304c4054871/nihms233581f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/125545a4cd9c/nihms233581f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/313f6b028555/nihms233581f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/bdfdc9f46695/nihms233581f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/fdabdb1e04f3/nihms233581f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/788dba5d1eb0/nihms233581f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/1304c4054871/nihms233581f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/125545a4cd9c/nihms233581f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/313f6b028555/nihms233581f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/bdfdc9f46695/nihms233581f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ee5d/3020987/fdabdb1e04f3/nihms233581f6.jpg

相似文献

1
A positive feedback loop of ER-α36/EGFR promotes malignant growth of ER-negative breast cancer cells.雌激素受体-α36/表皮生长因子受体正反馈环路促进雌激素受体阴性乳腺癌细胞的恶性生长。
Oncogene. 2011 Feb 17;30(7):770-80. doi: 10.1038/onc.2010.458. Epub 2010 Oct 11.
2
Estrogen receptor-alpha 36 mediates mitogenic antiestrogen signaling in ER-negative breast cancer cells.雌激素受体-α 36 介导 ER 阴性乳腺癌细胞中的有丝分裂型抗雌激素信号转导。
PLoS One. 2012;7(1):e30174. doi: 10.1371/journal.pone.0030174. Epub 2012 Jan 19.
3
Involvement of ER-α36, Src, EGFR and STAT5 in the biphasic estrogen signaling of ER-negative breast cancer cells.雌激素受体-α36、Src、表皮生长因子受体和信号转导子和转录激活子 5 在雌激素受体阴性乳腺癌细胞双相雌激素信号中的作用。
Oncol Rep. 2012 Jun;27(6):2057-65. doi: 10.3892/or.2012.1722. Epub 2012 Mar 15.
4
Estrogen receptor variant ER-α36 facilitates estrogen signaling via EGFR in glioblastoma.雌激素受体变体 ER-α36 通过表皮生长因子受体(EGFR)促进胶质母细胞瘤中的雌激素信号传导。
Cell Biol Int. 2022 Nov;46(11):1759-1774. doi: 10.1002/cbin.11877. Epub 2022 Aug 5.
5
Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.雌激素对丝裂原活化蛋白激酶的激活是由雌激素受体α36(ER-α36)在雌激素受体阳性乳腺癌细胞中介导的。
J Steroid Biochem Mol Biol. 2014 Sep;143:434-43. doi: 10.1016/j.jsbmb.2014.06.009. Epub 2014 Jun 25.
6
A positive cross-regulation of HER2 and ER-α36 controls ALDH1 positive breast cancer cells.HER2 和 ER-α36 的正交叉调控控制着 ALDH1 阳性乳腺癌细胞。
J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):262-8. doi: 10.1016/j.jsbmb.2011.08.011. Epub 2011 Sep 3.
7
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.雌激素受体-α36(ER-α36)是雌激素受体-α(ER-α)的一种变体,通过 MAPK/ERK 和 PI3K/Akt 通路促进子宫内膜癌细胞中他莫昔芬激动剂的作用。
PLoS One. 2010 Feb 2;5(2):e9013. doi: 10.1371/journal.pone.0009013.
8
ER-α36 mediates cisplatin resistance in breast cancer cells through EGFR/HER-2/ERK signaling pathway.ER-α36 通过 EGFR/HER-2/ERK 信号通路介导乳腺癌细胞对顺铂的耐药性。
J Exp Clin Cancer Res. 2018 Jun 25;37(1):123. doi: 10.1186/s13046-018-0798-z.
9
Estrogen receptor-α36 is involved in icaritin induced growth inhibition of triple-negative breast cancer cells.雌激素受体-α36参与淫羊藿素诱导的三阴性乳腺癌细胞生长抑制。
J Steroid Biochem Mol Biol. 2017 Jul;171:318-327. doi: 10.1016/j.jsbmb.2017.05.009. Epub 2017 May 18.
10
The ER-α36/EGFR signaling loop promotes growth of hepatocellular carcinoma cells.雌激素受体α36/表皮生长因子受体信号转导环促进肝癌细胞生长。
Steroids. 2018 Jun;134:78-87. doi: 10.1016/j.steroids.2018.02.007. Epub 2018 Feb 23.

引用本文的文献

1
ERα36 Promotes -Mediated Adriamycin Resistance via Non-Genomic Signaling in Triple-Negative Breast Cancer.雌激素受体α36通过非基因组信号通路促进三阴性乳腺癌中的阿霉素耐药性。
Int J Mol Sci. 2025 Jul 25;26(15):7200. doi: 10.3390/ijms26157200.
2
Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.孟德尔随机化研究确定与乳腺癌风险相关的免疫细胞表型。
Discov Oncol. 2025 Feb 19;16(1):205. doi: 10.1007/s12672-025-01963-z.
3
Disrupted Lipid Metabolism, Cytokine Signaling, and Dormancy: Hallmarks of Doxorubicin-Resistant Triple-Negative Breast Cancer Models.

本文引用的文献

1
ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.雌激素受体-α36(ER-α36)是雌激素受体-α(ER-α)的一种变体,通过 MAPK/ERK 和 PI3K/Akt 通路促进子宫内膜癌细胞中他莫昔芬激动剂的作用。
PLoS One. 2010 Feb 2;5(2):e9013. doi: 10.1371/journal.pone.0009013.
2
Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36.苯乙基异硫氰酸酯通过下调雌激素受体-α36 抑制乳腺癌细胞生长。
J Cell Mol Med. 2010 Jun;14(6B):1485-93. doi: 10.1111/j.1582-4934.2009.00877.x. Epub 2009 Oct 15.
3
脂质代谢紊乱、细胞因子信号传导与休眠:多柔比星耐药三阴性乳腺癌模型的特征
Cancers (Basel). 2024 Dec 23;16(24):4273. doi: 10.3390/cancers16244273.
4
Obesity-Senescence-Breast Cancer: Clinical Presentation of a Common Unfortunate Cycle.肥胖-衰老-乳腺癌:一个常见不幸循环的临床表现。
Adv Exp Med Biol. 2024;1460:821-850. doi: 10.1007/978-3-031-63657-8_27.
5
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer.乳腺癌中雌激素受体信号通路的基础研究综述
Int J Mol Sci. 2023 Apr 6;24(7):6834. doi: 10.3390/ijms24076834.
6
E3 ligase ligand optimization of Clinical PROTACs.临床PROTACs的E3连接酶配体优化
Front Chem. 2023 Jan 17;11:1098331. doi: 10.3389/fchem.2023.1098331. eCollection 2023.
7
The essential role of YAP in ERα36-mediated proliferation and the epithelial-mesenchymal transition in MCF-7 breast cancer cells.YAP在雌激素受体α36(ERα36)介导的MCF-7乳腺癌细胞增殖及上皮-间质转化中的重要作用。
Front Pharmacol. 2022 Dec 2;13:1057276. doi: 10.3389/fphar.2022.1057276. eCollection 2022.
8
Localisation of oestrogen receptors in stem cells and in stem cell-derived neurons of the mouse.雌激素受体在小鼠干细胞及其衍生神经元中的定位。
J Neuroendocrinol. 2023 Feb;35(2):e13220. doi: 10.1111/jne.13220. Epub 2022 Dec 12.
9
Identification of a novel signature with prognostic value in triple-negative breast cancer through clinico-transcriptomic analysis.通过临床转录组分析鉴定三阴性乳腺癌中具有预后价值的新特征。
Ann Transl Med. 2022 Oct;10(20):1095. doi: 10.21037/atm-22-1931.
10
Hypomorphism of a Novel Long ERα Isoform Causes Severe Reproductive Dysfunctions in Female Mice.新型长 ERα 异构体的功能降低导致雌性小鼠严重生殖功能障碍。
Endocrinology. 2022 Oct 23;163(12). doi: 10.1210/endocr/bqac160.
Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer.
雌激素受体α的新型变体ER-α36的表达与乳腺癌对他莫昔芬治疗的耐药性
J Clin Oncol. 2009 Jul 20;27(21):3423-9. doi: 10.1200/JCO.2008.17.2254. Epub 2009 Jun 1.
4
Estrogen receptor-alpha (ER-alpha) suppresses expression of its variant ER-alpha 36.雌激素受体α(ER-α)抑制其变体ER-α 36的表达。
FEBS Lett. 2009 Apr 17;583(8):1368-74. doi: 10.1016/j.febslet.2009.03.047. Epub 2009 Mar 26.
5
ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas.雌激素受体α36(ER-α36)是雌激素受体α的一种新型变体,在雌激素受体阳性和阴性的人类乳腺癌中均有表达。
Anticancer Res. 2008 Jan-Feb;28(1B):479-83.
6
Loss of tumourigenicity of stably ERbeta-transfected MCF-7 breast cancer cells.稳定转染雌激素受体β的MCF-7乳腺癌细胞致瘤性的丧失
Mol Cell Endocrinol. 2007 Aug 15;274(1-2):19-29. doi: 10.1016/j.mce.2007.05.012. Epub 2007 May 24.
7
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.美国临床肿瘤学会/美国病理学家学会关于乳腺癌中人表皮生长因子受体2检测的指南建议
J Clin Oncol. 2007 Jan 1;25(1):118-45. doi: 10.1200/JCO.2006.09.2775. Epub 2006 Dec 11.
8
A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling.雌激素受体-α的一种变体,hER-α36:雌激素和抗雌激素依赖性膜启动有丝分裂信号转导
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9063-8. doi: 10.1073/pnas.0603339103. Epub 2006 Jun 5.
9
Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66.人雌激素受体α66的新型变体——人雌激素受体α36的鉴定、克隆与表达
Biochem Biophys Res Commun. 2005 Nov 4;336(4):1023-7. doi: 10.1016/j.bbrc.2005.08.226.
10
Distinctive actions of membrane-targeted versus nuclear localized estrogen receptors in breast cancer cells.膜靶向雌激素受体与核定位雌激素受体在乳腺癌细胞中的独特作用。
Mol Endocrinol. 2005 Jun;19(6):1606-17. doi: 10.1210/me.2004-0468. Epub 2005 Apr 14.